Top

Published in:

01-09-2010 | Invited Review

Meningiomas and neurofibromatosis

Authors: Stéphane Goutagny, Michel Kalamarides

Published in: Journal of Neuro-Oncology | Issue 3/2010

Abstract

Neurofibromatosis type 2 (NF2) is a rare genetic disorder predisposing to multiple benign tumors of the nervous system. Meningiomas occur in about half of NF2 patients, and are often multiple. Patients harboring seemingly isolated multiple meningiomas should be investigated to diagnose NF2 by careful familial history collection, detailed clinical examination (skin lesions and slit lamp examination of the lens), audiovestibular testing, and fine cranio-spinal Magnetic Resonance Imaging. Somatic mosaicism is frequent in NF2 and may explain a mild phenotype as, e.g. isolated multiple meningiomas. Neurofibromatosis type 1 is not associated with an increased risk of meningioma. Whether meningiomas are part of the schwannomatosis tumor phenotype or not remains debated. Meningiomas in NF2 patients are associated with a higher risk of mortality, and their treatment is challenging, but data about natural history of meningiomas in NF2 patients in the literature are sparse. Thus, knowledge of tumor behavior is essential in slow growing tumors like meningiomas, to balance the risk of treatment against the natural history of the disease, and to evaluate the efficiency of alternative therapeutics (radiation therapy or new drugs).

Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332CrossRefPubMed

Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618PubMed

Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450–461CrossRefPubMed

Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM (1996) The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38:880–885CrossRefPubMed

Drouet A, Créange A (2005) Polyneuropathy associated with neurofibromatosis. Rev Neurol (Paris) 161:275–283

McLaughlin ME, Pepin SM, Maccollin M, Choopong P, Lessell S (2007) Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 125:389–394CrossRefPubMed

Bosch MM, Boltshauser E, Harpes P, Landau K (2006) Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 141:1068–1077CrossRefPubMed

Otsuka G, Saito K, Nagatani T, Yoshida J (2003) Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2. J Neurosurg 99:480–483CrossRefPubMed

Antinheimo J, Haapasalo H, Haltia M, Tatagiba M, Thomas S, Brandis A, Sainio M, Carpen O, Samii M, Jääskeläinen J (1997) Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 87:610–614CrossRefPubMed

10.

Ruggieri M, Iannetti P, Polizzi A, Mantia IL, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21–34CrossRefPubMed

11.

Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH (2001) Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 60:994–1003PubMed

12.

Germano IM, Edwards MS, Davis RL, Schiffer D (1994) Intracranial meningiomas of the first two decades of life. J Neurosurg 80:447–453CrossRefPubMed

13.

Evans DG, Birch JM, Ramsden RT (1999) Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496–499CrossRefPubMed

14.

Rochat P, Johannesen HH, Gjerris F (2004) Long-term follow up of children with meningiomas in Denmark: 1935 to 1984. J Neurosurg 100:179–182PubMed

15.

Rushing EJ, Olsen C, Mena H, Rueda M-E, Lee Y-S, Keating RF, Packer RJ, Santi M (2005) Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg 103:489–495PubMed

16.

Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DGR (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:715–723CrossRefPubMed

17.

Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76PubMed

18.

Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40:109–114CrossRefPubMed

19.

Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DGR (2003) Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 40:459–463CrossRefPubMed

20.

Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T (1998) Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 63:727–736PubMed

21.

Evans DGR, Watson C, King A, Wallace AJ, Baser ME (2005) Multiple meningiomas: differential involvement of the NF2 gene in children and adults. J Med Genet 42:45–48CrossRefPubMed

22.

Larson JJ, Tew JM, Simon M, Menon AG (1995) Evidence for clonal spread in the development of multiple meningiomas. J Neurosurg 83:705–709CrossRefPubMed

23.

Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP (1993) Familial meningioma is not allelic to neurofibromatosis 2. Neurology 43:2096–2098PubMed

24.

Maxwell M, Shih SD, Galanopoulos T, Hedley-Whyte ET, Cosgrove GR (1998) Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin Report of two cases. J Neurosurg 88:562–569CrossRefPubMed

25.

Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF (2009) Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics 2:42CrossRefPubMed

26.

Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMed

27.

Slattery WH, Lev MH, Fisher LM, Connell SS, Iqbal Z, Go JL (2005) NF2 Natural History Consortium MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation. Otol Neurotol 26:733–740CrossRefPubMed

28.

Mohyuddin A, Neary WJ, Wallace A, Wu CL, Purcell S, Reid H, Ramsden R, Read A, Black G, Evans DGR (2002) Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 39:315–322CrossRefPubMed

29.

Evans DGR, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A (2007) Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet 71:354–358CrossRefPubMed

30.

McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, Kingston H, Super M, Harris R, Evans DG (1999) A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36:197–203PubMed

31.

Créange A, Zeller J, Rostaing-Rigattieri S, Brugières P, Degos JD, Revuz J, Wolkenstein P (1999) Neurological complications of neurofibromatosis type 1 in adulthood. Brain 122:473–481CrossRefPubMed

32.

MacCollin M, Woodfin W, Kronn D, Short MP (1996) Schwannomatosis: a clinical and pathologic study. Neurology 46:1072–1079PubMed

33.

MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES (2005) Diagnostic criteria for schwannomatosis. Neurology 64:1838–1845CrossRefPubMed

34.

Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG (2010) SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet. doi:10.1136/jmg.2009.075721

35.

Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR (2008) Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 74:358–366CrossRefPubMed

36.

Hulsebos TJM, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80:805–810CrossRefPubMed

37.

Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, Vivarelli R, Genuardi M, Papi L (2010) Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 11:73–80CrossRefPubMed

38.

Perry A, Kurtkaya-Yapicier O, Scheithauer BW, Robinson S, Prayson RA, Kleinschmidt-DeMasters BK, Stemmer-Rachamimov AO, Gutmann DH (2005) Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. Brain Pathol 15:55–65

39.

Cunliffe IA, Moffat DA, Hardy DG, Moore AT (1992) Bilateral optic nerve sheath meningiomas in a patient with neurofibromatosis type 2. Br J Ophthalmol 76:310–312CrossRefPubMed

40.

Kolles H, Niedermayer I, Schmitt C, Henn W, Feld R, Steudel WI, Zang KD, Feiden W (1995) Triple approach for diagnosis and grading of meningiomas: histology morphometry of Ki-67/Feulgen stainings and cytogenetics. Acta Neurochir (Wien) 137:174–181CrossRef

41.

Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, von Deimling A (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827–832PubMed

42.

Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Deprez RLD, Zwarthoff E (2001) NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367–372CrossRefPubMed

43.

Lamszus K, Vahldiek F, Mautner VF, Schichor C, Tonn J, Stavrou DF et al (2000) Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 59:504–512PubMed

44.

Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control complications and hearing preservation rates. Neurosurgery 60:460–470PubMed

45.

Kondziolka D, Madhok R, Lunsford LD, Mathieu D, Martin JJ, Niranjan A, Flickinger JC (2009) Stereotactic radiosurgery for convexity meningiomas. J Neurosurg 111:458–463CrossRefPubMed

46.

Wentworth S, Pinn M, Bourland JD, Deguzman AF, Ekstrand K, Ellis TL, Glazier SS, McMullen KP, Munley M, Stieber VW, Tatter SB, Shaw EG (2009) Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys 73:208–213PubMed

47.

Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43:289–294CrossRefPubMed

48.

Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367CrossRefPubMed

49.

Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D et al (2009) Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 15:5032–5039CrossRefPubMed

50.

Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M (2002) Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060–1065CrossRefPubMed

51.

Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M (2008) Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol 18:62–70CrossRefPubMed

Title: Meningiomas and neurofibromatosis
Authors: Stéphane Goutagny
Michel Kalamarides
Publication date: 01-09-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0339-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Meningiomas and neurofibromatosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Epidemiology and etiology of meningioma

Surgical navigation for meningioma surgery

Modern meningioma imaging techniques

FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients

Medical therapies for meningiomas

Opportunities for clinical research in meningioma